期刊文献+

代谢综合征血脂异常的特点及治疗研究进展 被引量:15

Characteristics of and Therapy for Dyslipidemia in Metabolic Syndrome
下载PDF
导出
摘要 代谢综合征具有多种心血管疾病的危险因素。其核心成分之一血脂异常易致动脉粥样硬化,主要有高三酰甘油、低高密度脂蛋白胆固醇和小而密低密度脂蛋白胆固醇升高。降脂治疗的基本措施是改善生活方式,药物治疗包括他汀类、贝特类、烟酸、依折麦布、胆固醇酯转运蛋白抑制剂等及联合治疗。 The metabolic syndrome is a multiplex risk factor for atherosclerotic cardiovascular disease.The core components of the dyslipidemia of the metabolic syndrome are the "lipid triad" of high plasma triglycerides,low levels of high-density lipoprotein cholesterol,and many small,dense low-density lipoprotein particles.The cornerstone of therapy for this is lifestyle change.If this does not correct the dyslipidemia,drug therapy may be required.Several drugs have been described for the management of the dyslipidemia including fibrates,ezetimibe,niacin,cholesteryl ester transfer protein inhibitors,as well as combined treatment regimes.
出处 《心血管病学进展》 CAS 2011年第1期104-107,共4页 Advances in Cardiovascular Diseases
关键词 代谢综合征 血脂异常 治疗 metabolic syndrome dyslipidemia therapy
  • 相关文献

参考文献16

  • 1Raijman I, Kenall M J, Cramb R, et al. Investigation of low density lipoprotein subfractions as a coronary risk factor in normotriglyceridaemic men[ J ]. Athero- sclerosis, 1996,125 ( 2 ) : 231-242.
  • 2Robins SJ, Collins D, Wittes JT, et al. Veterans Affairs High-Density Lipo- mtein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events[ J]. JAMA ,2007,285 : 1585-1591.
  • 3Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in pa- tients with cardiumetabolic risk: consensus statement from the American Diabe- tes Association and the American Conegeof Cardiology foundation [ J]. Diab Care ,2008,31:811 -822.
  • 4Dennis TV, Bernard VM, Marian B, et al. Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults [ J ]. Am J Clin Nutr, 2006,84:1317-1323.
  • 5Akesson A, Weismayer C, Newby PK, et al. Combined effect of low-risk dieta- ry and lifestyle behaviors in primary prevention of myocardial infarction in women [ J ]. Arch Intern Med,2007,167 (19) :2122-2127.
  • 6Westman EC, Feinman RD, Mavropoulos JC, et al. Low-carbohydrate nutrition and metabolism [ J ]. Am J Clin Nutr, 2007,86 (2) :276-284.
  • 7Bahadir MA, Oquz A, Uzunlulu M, et al. Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome [ J]. Atheroscler Thromb,2009,16 (5) :684-690.
  • 8Rosenson RS, Wolff DA, Huskin AL, et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome [ J ]. Diabetes Care ,2007,30 : 1945-1951.
  • 9Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipi- demia in the metabolic syndrome [ J ] ? Artefioscler Thromb Vase Biol, 2008,28: 39-46.
  • 10Bodor ET, Offermanns S. Nicotinic acid: an old drug with a promising future [ J]. Br J Pharmacol,2008,153 :S68-75.

同被引文献169

引证文献15

二级引证文献103

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部